All In Biotech

Drug Trial Radar · NCT03694392

Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years

Examining Vaccine Effectiveness (VE) of Flublok Relative to Standard Dose Inactivated Influenza Vaccine Among Kaiser Permanente Northern California Members Aged 18-64 Years

Last checked: Nov 20, 2026Latest source record: Apr 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

2,776,278

Actual

Start

Sep 16, 2018

Primary completion

Apr 9, 2021

Study completion Dec 31, 2022

Sponsor

Lead sponsor
Kaiser PermanenteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Sanofi Pasteur, a Sanofi Company
First posted
Oct 3, 2018

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The overall objective of this study is to describe the effectiveness of Flublok Quadrivalent vaccine compared to standard dose inactivated influenza vaccine (SD-IIV) in adults 18 through 64 years of age. During this study, Flublok Quadrivalent or SD-IIV will be administered according to the guidelines in the Prescribing Information materials and only to persons for whom it is indicated. The 2018-2019, 2019-2020, and 2020-2021 formulations of recombinant influenza vaccine (Flublok Quadrivalent vaccine) and SD-IIV will be evaluated for outcomes including all polymerase chain reaction (PCR)-confirmed influenza, PCR-confirmed hospitalized influenza, hospitalized community-acquired pneumonia and cardio-respiratory events.

Conditions

  • Influenza
  • Pneumonia
  • Lower Respiratory Tract Infection
  • Acute Myocardial Infarction
  • Congestive Heart Failure
  • Stroke

Interventions

  • Flublok QuadrivalentBiological

    Flublok Quadrivalent vaccine is a recombinant hemagglutinin influenza vaccine indicated for active immunization against disease caused by influenza A subtype viruses and type B viruses contained in the vaccine for adults 18 years of age and older. Use of recombinant DNA techniques to produce vaccine antigen expressed in cell culture is a method that avoids growing the influenza viruses in embryonated hen's eggs.

  • Standard Dose Inactivated Influenza Vaccine (SD-IIV)Biological

    For the 2018-2019, 2019-2020, and 2020-2021 flu seasons, the primary SD-IIVs used will be Fluarix Quadrivalent and Flulaval Quadrivalent.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Adults 50-64 Years Old With Polymerase-chain Reaction (PCR) Confirmed Influenza TestsTime frame: Up to 8 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Kaiser Permanente Northern California (entire region)

    Oakland, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.